1
|
Xu Q, Zhang W, Ma YX, He CN, Zhang LT, Abulitifu Y, Li Y, Wang N, Wang HL, Zhao YY, Gao X, Gao PG, Su XY, Li S, Liu YY, Guo F, Chen ZQ, Liu HL, Gao XQ, Fu JJ, Yu GY, Wang XZ, Wang JP, Zhang YP, Ji FP. [Twelve-week of sofosbuvir/velpatasvir therapeutic regimen for chronic hepatitis C patients in northwest region of China: a real-world multicenter clinical study]. Zhonghua Gan Zang Bing Za Zhi 2021; 29:1046-1052. [PMID: 34933421 DOI: 10.3760/cma.j.cn501113-20201010-00548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Objective: To study the real-world outcome of China FDA-approved Sofosbuvir (SOF)/Velpatasvir (VEL) in Northwest China. Methods: In this multicenter, prospective, real-world cohort study, we recruited patients from 10 sites from Northwest China, who were chronically infected with HCV GTs 1-6 from 06/2018 to 09/2019. Patients received SOF (400mg)/VEL (100mg) for 12 weeks, and with ribavirin 900-1200 mg for GT3 cirrhosis and for any genotype decompensated cirrhosis. The primary endpoint was sustained virological response at 12-weeks post-treatment (SVR12) and safety. The secondary endpoint was the change of liver function after the achievement of SVR12. Results: Totally, 143 patients were enrolled in the study, four patients were lost to follow-up and one died during the follow-up, 138 patients were included in per-protocol analysis. Of the 138 patients, the mean age 53 years, 53.6% male, 94.2% Han nationality, 53.6% liver cirrhosis, 10.1% HBsAg(+), 6.5% renal dysfunction, 5.1% treatment-experienced, and 16.7% patients received ribavirin treatment. The genotype distribution was as follows: 35.5% GT1, 42.8% GT2, 15.9% GT3, and 5.8% un-typed. The SVR12 rate was 96.5% (138/143, 95%CI: 93.5%-99.6%) for intention-to-treat analysis, and in per-protocol analysis, all 138 patients obtained SVR12 (100%). Compared with baseline, the serum total bilirubin, ALT and AFP levels decreased (all P < 0.05), as well as increased ALB and platelet count (all P < 0.001) at post-treatment 12-weeks. Overall adverse events (AEs) rate is 29.0%, and the most common AEs were anemia (14.5%) and fatigue (8.0%). Severe side effects (edema and fatigue) occurred in 2 patients, one of whom needed a short-term interruption of treatment due to fatigue. Conclusion: In this real-world cohort study, 12-week SOF/VEL regimen with or without ribavirin achieved high SVR12 rates (96.5%-100% overall) with excellent safety profile among patients with HCV GT1/2/3 infection including patients with GT3 and cirrhosis, and led to improvement of liver function.
Collapse
Affiliation(s)
- Q Xu
- Hospital of Traditional Chinese Medicine Affiliated to Xinjiang Medical University, Urumqi 830000, China
| | - W Zhang
- Xijing Hospital of Air Force Medical University, Xi'an 710032, China
| | - Y X Ma
- The Fourth People's Hospital of Qinghai Province, Xining 810000, China
| | - C N He
- The Second Affiliated Hospital of Xi'an, Xi'an Jiaotong University, Xi'an 710004, China Shaanxi Provincial Shenmu Hospital, Yulin 719300, China
| | - L T Zhang
- First Hospital of Lanzhou University, Lanzhou 730000, China
| | - Yilihamu Abulitifu
- People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China
| | - Y Li
- Shaanxi Provincial People's Hospital, Xi'an 710068, China
| | - N Wang
- The Affiliated Xi'an Central Hospital of Xi'an Jiaotong University, Xi'an 710003, China
| | - H L Wang
- The Eighth hospital of Xi'an City, Xi'an 710061, China
| | - Y Y Zhao
- The Second Affiliated Hospital of Xi'an, Xi'an Jiaotong University, Xi'an 710004, China
| | - X Gao
- The Second Affiliated Hospital of Xi'an, Xi'an Jiaotong University, Xi'an 710004, China
| | - P G Gao
- The Second Affiliated Hospital of Xi'an, Xi'an Jiaotong University, Xi'an 710004, China
| | - X Y Su
- The Second Affiliated Hospital of Xi'an, Xi'an Jiaotong University, Xi'an 710004, China
| | - S Li
- Shaanxi Provincial Centre for Disease Control and Prevention, Xi'an 710054, China
| | - Y Y Liu
- The Affiliated Xi'an Central Hospital of Xi'an Jiaotong University, Xi'an 710003, China
| | - F Guo
- Hospital of Traditional Chinese Medicine Affiliated to Xinjiang Medical University, Urumqi 830000, China
| | - Z Q Chen
- Xijing Hospital of Air Force Medical University, Xi'an 710032, China
| | - H L Liu
- Central Hospital of Xianyang City, Xianyang 712000, China
| | - X Q Gao
- The Fourth People's Hospital of Qinghai Province, Xining 810000, China
| | - J J Fu
- The Affiliated Xi'an Central Hospital of Xi'an Jiaotong University, Xi'an 710003, China
| | - G Y Yu
- The Fourth People's Hospital of Qinghai Province, Xining 810000, China
| | - X Z Wang
- Hospital of Traditional Chinese Medicine Affiliated to Xinjiang Medical University, Urumqi 830000, China
| | - J P Wang
- Xijing Hospital of Air Force Medical University, Xi'an 710032, China
| | - Y P Zhang
- People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China
| | - F P Ji
- The Second Affiliated Hospital of Xi'an, Xi'an Jiaotong University, Xi'an 710004, China National & Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, the Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an 710004, China Shaanxi Provincial Clinical Medical Research Center of Infectious Diseases, Xi'an 710049, China
| |
Collapse
|